- Posted Wednesday June 5, 2013
TGen's Huentelman and Weiss named to 2013 Class of 40 Under 40
Newspaper recognizes TGen researchers among Phoenix's brightest young leaders
PHOENIX, Ariz. - June 5, 2013 - Dr. Matt
Huentelman of the Translational Genomics Research Institute (TGen)
and Dr. Glen Weiss of TGen and Cancer Treatment Centers of America®
(CTCA) are among the 40 business leaders under 40 years of age
named by the Phoenix Business Journal to its 13th Annual
Class of 40 Under 40.
They will be honored at an awards ceremony June 27 at the Phoenix Art Museum.
Dr. Huentelman, Ph.D., is an Associate Professor in TGen's Neurogenomics Division, where he oversees research programs focused on sensory disorders, including hearing and vision loss, and on aging and age-related diseases, such as Alzheimer's disease and the genetics of learning and memory - highlighted recently by the launch of TGen's MindCrowd project (www.MindCrowd.org).
Dr. Huentelman also is the Co-Director of TGen's Center for Rare Childhood Disorders, which investigates uncommon neurologic problems among children, often those that are only a collection of symptoms with no diagnosis.
"I am honored to be selected among the 40 Under 40 by the Phoenix Business Journal," Dr. Huentelman said. "This recognition serves to highlight the significant advances that TGen has made through the study of the human genome, and the insights and breakthroughs being made, not only by me, but by our entire scientific staff every day."
Dr. Weiss, M.D., is a Clinical Associate Professor in TGen's Cancer and Cell Biology Division and is Director of Clinical Research at CTCA®. His research focuses on genomic and other 'omics characterizations of lung cancer, rare cancers and early-detection strategies.
Dr. Weiss has been selected by CTCA at Western Regional Medical Center to head the startup of a new clinical research program in Goodyear, Ariz. Dr. Weiss is also Co-Unit Head of TGen's Lung Cancer Research Laboratory.
"As a research scientist, being a member of the 40 Under 40 is a reflection of the collaborations I am privileged to conduct through TGen and CTCA," Dr. Weiss said. "As a medical doctor, these collaborations lead to new therapies that can help the patients that look to us for healing and hope."
The 40 Under 40 program's hundreds of alumni includes Phoenix Mayor Greg Stanton, a member of the TGen Board of Directors, and Arizona Diamondbacks President Derrick Hall, a member of TGen's National Advisory Council for Pancreatic Cancer Research.
# # #
About Cancer Treatment Centers of America
Cancer Treatment Centers of America, Inc. (CTCA) is a national network of hospitals focusing on complex and advanced stage cancer. CTCA offers a comprehensive, fully integrated approach to cancer treatment and serves patients from all 50 states at facilities located in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Known for delivering the Mother Standard® of care and Patient Empowerment Medicine®, CTCA provides patients with information about cancer and their treatment options so they can control their treatment decisions. For more information about CTCA, go to www.cancercenter.com.
Social Media Manager
Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. TGen is focused on helping patients with cancer, neurological disorders and diabetes, through cutting edge translational research (the process of rapidly moving research towards patient benefit). TGen physicians and scientists work to unravel the genetic components of both common and rare complex diseases in adults and children. Working with collaborators in the scientific and medical communities literally worldwide, TGen makes a substantial contribution to help our patients through efficiency and effectiveness of the translational process. For more information, visit:www.tgen.org.
TGen Senior Science Writer